52.5% reduction with high-dose and 47.7% reduction with low-dose combination compared to baseline, and an acceptable tolerability profile. Novel investigational drug leverages SGLT2 inhibition and high selectivity ETA receptor antagonism with potential to deliver step-change efficacy and acceptable fluid retention.